<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Andrea</forename><surname>Zanichelli</surname></persName>
							<email>andrea.zanichelli@unimi.it</email>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Hilary</forename><forename type="middle">J</forename><surname>Longhurst</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Immunology</orgName>
								<orgName type="institution">Barts Health NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD z ;</roleName><forename type="first">Marcus</forename><surname>Maurer</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Allergie-Centrum-Charité</orgName>
								<address>
									<settlement>CharitéeUniversitätsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, PhD x ;</roleName><forename type="first">Laurence</forename><surname>Bouillet</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">National Reference Centre for Angioedema</orgName>
								<orgName type="department" key="dep2">Internal Medicine Department</orgName>
								<orgName type="institution">Grenoble University Hospital</orgName>
								<address>
									<settlement>Grenoble</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Werner</forename><surname>Aberer</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Dermatology and Venereology</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">jj Shire</orgName>
								<address>
									<settlement>Zug</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD jj ;</roleName><forename type="first">Vincent</forename><surname>Fabien</surname></persName>
						</author>
						<author>
							<persName><roleName>MD jj</roleName><forename type="first">Irmgard</forename><surname>Andresen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Teresa</forename><surname>Caballero</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="laboratory">IOS Study Group</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Department of Biomedical and Clinical Sciences Luigi Sacco</orgName>
								<orgName type="institution" key="instit1">University of Milan</orgName>
								<orgName type="institution" key="instit2">ASST Fatebenefratelli Sacco</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Allergy Department</orgName>
								<orgName type="department" key="dep2">Biomedical Research Network on Rare Diseases (CIBERER</orgName>
								<orgName type="institution">Hospital La Paz Institute for Health Research</orgName>
								<address>
									<postCode>U754)</postCode>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco</orgName>
								<orgName type="institution">Università degli Studi di Milano-Ospedale Luigi Sacco</orgName>
								<address>
									<addrLine>Via G.B. Grassi 74</addrLine>
									<postCode>20157</postCode>
									<settlement>Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">90472444684E68D5718D39F01625F2F3</idno>
					<idno type="DOI">10.1016/j.anai.2016.08.014</idno>
					<note type="submission">Received for publication May 15, 2016. Received in revised form August 5, 2016. Accepted for publication August 10, 2016. Dr Zanichelli reported receiving speaker fees from CSL Behring, Shire, Sobi, and ViroPharma (now part of the Shire Group of Companies); receiving consultancy fees from CSL Behring, Shire, and ViroPharma; and acting on the medical/advisory boards for CSL Behring and Shire. Dr Longhurst reported receiving research grant support and/or speaker/consultancy fees from BioCryst, CSL Behring, Dyax, Shire, Sobi, and ViroPharma. Dr Maurer reported receiving research grant support and/or speaker/consultancy fees from BioCryst, CSL Behring, Dyax, Shire/ Jerini AG, and ViroPharma. Dr Bouillet reported receiving honoraria from CSL Behring, Pharming, Shire, and ViroPharma, and her institute has received research funding from CSL Behring and Shire. Dr Aberer reported acting as a medical adviser</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) causes swelling in the skin and upper airways and pain in the abdomen because of mucosal swelling.</s><s>C1-INH-HAE is frequently misdiagnosed, leading to delays in diagnosis, inadequate treatment, and unnecessary procedures.</s><s>Objective: To evaluate the history of misdiagnosis in patients participating in the Icatibant Outcome Survey (IOS).</s><s>Methods: The IOS is an observational study in which safety and effectiveness of icatibant have been evaluated since 2009.</s><s>As part of the IOS, patients record any misdiagnoses received before being diagnosed as having C1-INH-HAE.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head><p><s>In January 2016, a total of 418 of 633 IOS patients with C1-INH-HAE type I or II had provided misdiagnosis data.</s><s>Of these, 185 of 418 (44.3%) received 1 or more prior misdiagnoses.</s><s>The most common misdiagnoses were allergic angioedema (103 of 185) and appendicitis (50 of 185).</s><s>A variety of other misdiagnoses were reported, including a substantial number of gastrointestinal disorders (excluding appendicitis).</s><s>Misdiagnosis rates were similar between males (41.1%) and females (46.5%) and between C1-INH-HAE type I (43.7%) and type II (51.6%).</s><s>Patients with family members diagnosed as having C1-INH-HAE were significantly less likely to be misdiagnosed than patients without a family history (140 of 366 [41.7%] vs 38 of 58 [65.5%], respectively; P ¼ .001).</s><s>Patients with a prior misdiagnosis had longer median delay to C1-INH-HAE diagnosis (13.3 years) than patients without (1.7 years; P &lt; .001).</s><s>Conclusion: From this large database, approximately 50% of patients with C1-INH-HAE type I or II have previously had their conditions misdiagnosed, most commonly as allergic angioedema or appendicitis.</s><s>Misdiagnosis results in marked delays in receiving the correct diagnosis, during which time patients cannot access effective, lifesaving treatment.</s><s>Trial Registration: ClinicalTrials.gov:</s><s>NCT01034969.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare autosomal dominant condition that causes recurrent episodic edema without wheals of the skin, abdomen, and upper airways, which can lead to fatal obstruction.</s><s><ref type="bibr">1e6</ref> Two phenotypic variants of C1-INH-HAE have been described: type I, in which antigenic and functional plasma C1-INH levels are below normal range, and type II, in which antigenic C1-INH levels are normal but functional C1-INH levels are below normal. <ref type="bibr" target="#b3">4</ref></s><s>This disease is estimated to occur in approximately 1 in 50,000 individuals worldwide.</s><s>C1-INH-HAE has substantial variability in disease manifestations, and symptoms such as swelling and pain can overlap with other more common allergic and gastrointestinal conditions.</s><s>14e17 Patients with C1-INH-HAE typically experience more than a 10-year delay in diagnosis, <ref type="bibr" target="#b10">11</ref> and delays in reaching a correct diagnosis can have significant consequences for the patient, particularly if the edema involves the laryngeal tissues with an associated increased risk of suffocation. <ref type="bibr" target="#b5">6</ref></s><s>he issue of misdiagnosis and its consequences has been previously explored in case studies, post hoc medical record reviews, and country-specific patient registries. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b14">14,</ref><ref type="bibr" target="#b16">16</ref></s><s>To better characterize this issue, the clinical aspects and trends of C1-INH-HAE misdiagnosis need to be investigated within a large, diverse, multinational, real-world patient population.</s><s>The Icatibant Outcome Survey (IOS) (ClinicalTrials.gov</s><s>Identifier: NCT01034969) is an ongoing, Shire-sponsored, international, prospective, observational registry that collects demographic, medical history, and clinical outcomes data in patients eligible for treatment with icatibant, a subcutaneously administered bradykinin B2 receptor antagonist, in the treatment of C1-INH-HAE. <ref type="bibr" target="#b18">18,</ref><ref type="bibr" target="#b19">19</ref></s><s>Analyses of data from patients participating in the IOS were conducted to help determine trends in C1-INH-HAE misdiagnosis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>The IOS observational registry, initiated in 2009, is being conducted at 50 participating sites in 11 countries (Austria, Brazil, Denmark, France, Germany, Greece, Israel, Italy, Spain, Sweden, and the United Kingdom) to monitor the safety and effectiveness of icatibant.</s><s>All patients provide written informed consent before participating in the IOS, and each participating study site operates in accordance with local ethics committees and/or health authorities, the Declaration of Helsinki, and the International Conference on Harmonisation Good Clinical Practice guidelines.</s></p><p><s>Patients with a diagnosis of C1-INH-HAE (type I or II), clinically confirmed by laboratory tests (C1-INH concentration and function), who were receiving or were a candidate for icatibant treatment were included in this analysis.</s><s>Patients attended regular follow-up visits, recommended every 6 months according to physician routine clinical practice.</s><s>Data were collected from electronic forms completed by physicians during routine patient visits.</s><s>Additional details of the IOS registry have been previously described. <ref type="bibr" target="#b20">20</ref></s><s>t enrollment, patients reported any misdiagnoses (based on HAE symptoms) received before the diagnosis of C1-INH-HAE.</s><s>Descriptive retrospective analyses of any reported misdiagnosis were performed using the IOS data collected from July 2009 to January 2016.</s><s>Descriptive statistics were used to compare patients who had 1 or more misdiagnoses with patients who had no misdiagnoses.</s><s>Statistical testing was considered exploratory in this observational study and no adjustment for multiplicity was performed.</s><s>Patients with a previous misdiagnosis also were compared by type of misdiagnosis, C1-INH-HAE type I or II, sex distribution, and familial history of C1-INH-HAE using descriptive statistics.</s><s>The Wilcoxon-Mann-Whitney test was used to compare continuous variables.</s><s>A c 2 test was used for comparisons between categories, with a statistical significance level of a ¼ 0.05.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Frequent</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Substantial Delays in Receiving the Correct Diagnosis</head><p><s>Patients with C1-INH-HAE who had a prior misdiagnosis experienced a significantly longer delay from symptom onset to C1-INH-HAE diagnosis (median, 13.3 years; range, À13.5 to 67.3 years) than patients without (median, 1.7 years; range, À41.8 to 66.9 years; P &lt; .001).</s><s>Misdiagnoses of nonallergic angioedema and biliary disorder resulted in the greatest mean time from symptoms to C1-INH-HAE diagnosis (Table <ref type="table" target="#tab_5">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This study found that patients with C1-INH-HAE commonly receive misdiagnoses, frequently allergic angioedema or appendicitis.</s><s>The present analysis is the first using IOS data to show that an initial misdiagnosis is a major driver of the long delays that patients    It is well recognized that patients with C1-INH-HAE can be subject to an initial misdiagnosis, but analyses of misdiagnosis patterns and trends in a real-world setting are scarce. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref></s><s>7e9 Moreover, angioedema is a widely variable disease with different types and subtypes, including acquired angioedema and idiopathic histaminergic angioedema. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref></s><s>It is understandable, therefore, that clinical suspicion for C1-INH-HAE may be low, particularly among physicians who are not familiar with the disorder or its clinical management.</s></p><p><s>Our findings suggest that C1-INH-HAE misdiagnoses are not influenced by patient sex or HAE type (I vs II).</s><s>A numerically higher percentage of males were diagnosed as having other nonallergic angioedema (P ¼ .12);</s><s>however, the broad range of misdiagnoses in this category and the relatively small number of patients prevent any substantial conclusions by sex.</s><s>Patients with a family history of C1-INH-HAE were significantly less likely to receive misdiagnoses, most likely because of consideration of positive family history in the differential diagnosis.</s><s>Physician awareness that in 25% of C1-INH-HAE cases there is no positive family history may help decrease misdiagnoses. <ref type="bibr" target="#b22">21</ref></s><s>Nevertheless, it is remarkable that almost half of patients with a family history of C1-INH-HAE received misdiagnoses.</s><s>This finding could represent an opportunity to improve diagnosis by encouraging family members to come forward for diagnosis and by facilitating diagnosis by primary care physicians.</s><s>Geographic region could potentially play a part in misdiagnosis rates, although similarly, the small number of patients with misdiagnosis data in each of the 11 countries precludes meaningful comparison.</s></p><p><s>Patients with C1-INH-HAE may present with abdominal pain, which is reflected in the range of gastrointestinal diagnoses patients in the current study report as being their initial diagnosis.</s><s>Importantly, angioedema that affects viscera or bowel is not necessarily associated with visible swelling, making a high index of suspicion and careful history taking that includes questions about peripheral or laryngeal swelling essential for a diagnosis of angioedema. <ref type="bibr" target="#b16">16,</ref><ref type="bibr" target="#b23">22</ref></s><s>n addition, patients with 1 or more misdiagnoses experienced a significantly longer delay that those without a misdiagnosis before receiving a correct C1-INH-HAE diagnosis.</s><s>A 2013 analysis of IOS data found a median diagnostic delay in patients with C1-INH-HAE type I or II across 8 European countries of 8.5 years (range, 0e62.0 years) <ref type="bibr" target="#b7">8</ref> ; however, that analysis, unlike the present study, did not account for prior misdiagnosis.</s><s>Given that the age of symptom onset in the present study is similar in both groups and those who   had a misdiagnosis tended to be older when C1-INH-HAE was correctly diagnosed, this delay can be attributed to the initial misdiagnosis.</s><s>An initial misdiagnosis can have practical consequences for patients with C1-INH-HAE that can range from increased risk of death from laryngeal edema <ref type="bibr" target="#b5">6</ref> to altering the treatment approach of subsequent health care professionals, delay of effective therapy, and prolonged issues associated with an otherwise manageable condition.</s><s>Patients with misdiagnoses included those with frequent attacks.</s><s>Given the age at onset of symptoms, delay in diagnosis is likely to lead to severe disruption of education and early working life and may account for many of the economic, social, and psychological consequences of C1-INH-HAE described elsewhere.</s><s><ref type="bibr">23e27</ref> In a recent study by Bygum et al, <ref type="bibr" target="#b25">24</ref> misdiagnosis was mentioned by patients as an important burden of their disease and was included in a conceptual model of C1-INH-HAE burden in patients.</s></p><p><s>Considering that published data regarding C1-INH-HAE misdiagnosis are scarce and consist largely of case reports and countryspecific analyses, the relatively large real-world multinational database used in this analysis substantially contributes to the understanding of this issue.</s><s>Limitations of this analysis necessarily include those related to patient recall, the number of patients analyzed, and the fact that the IOS currently includes only patients from centers in Europe, South America, and the Middle East.</s><s>Recent evidence from Japan, however, suggests that patients with HAE in non-IOS countries also experience long delays in diagnosis and similar rates of misdiagnosis. <ref type="bibr" target="#b29">28</ref></s><s>wareness of C1-INH-HAE has increased in recent years; however, patients continue to experience misdiagnoses, resulting in unnecessary treatment, delays in appropriate diagnosis and therapy, and increased risk of death. <ref type="bibr" target="#b5">6</ref></s><s>Increased awareness of C1-INH-HAE signs, symptoms, and prodromes, <ref type="bibr" target="#b30">29</ref></s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>the types of common C1-INH-HAE misdiagnoses, knowledge of C1-INH-HAE occurrence in the absence of a positive family history, and wide availability of C4 blood test screening, with C1-INH testing if suspicion is high, may assist physicians and patients in recognizing C1-INH-HAE as a possible cause of symptoms and encourage testing to confirm or rule out C1-INH-HAE.</s><s>Ongoing education for physicians who are most likely to encounter patients with C1-INH-HAE may reduce misdiagnosis and the delay in receiving a correct diagnosis and treatment.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>INH-HAE (140 of 336 [41.6%] vs 38 of 58 [65.5%];</s><s>P &lt; .001)</s><s>(Table 2).</s><s>The overall country-specific rate of C1-INH-HAE misdiagnosis from IOS patients is given in Table 3, Patient Characteristics in Those With and Without a Prior HAE Misdiagnosis</s></p></div></figDesc><table><row><cell cols="2">Misdiagnosis of C1-INH-HAE</cell><cell></cell></row><row><cell cols="3">As of January 2016, a total of 633 patients with C1-INH-HAE</cell></row><row><cell cols="3">(type I or II) were enrolled in the IOS. Of these, 418 patients</cell></row><row><cell cols="3">(66.0%) had provided misdiagnosis data. Almost half of these</cell></row><row><cell cols="3">patients (185 of 418 [44.3%]) had received 1 or more misdiagnoses</cell></row><row><cell cols="3">before being diagnosed as having C1-INH-HAE, whereas 223 of</cell></row><row><cell cols="3">418 (55.7%) had never had a misdiagnosis. Patients with and</cell></row><row><cell cols="3">without a prior misdiagnosis had similar demographics for sex,</cell></row><row><cell cols="3">C1-INH-HAE diagnosis (type I or II), ethnicity, and age at symptom</cell></row><row><cell cols="3">onset (Table 1). Patients with 1 or more misdiagnoses were</cell></row><row><cell cols="3">significantly older at the time of correct diagnosis (median age,</cell></row><row><cell cols="3">28.4 years; range, 3.8e77.3 years) than those without a misdiag-</cell></row><row><cell cols="3">nosis (median age, 16.7 years; range, 0.0e77.3 years; P &lt; .001).</cell></row><row><cell cols="3">Patients with family members with C1-INH-HAE were significantly</cell></row><row><cell cols="3">less likely to receive an initial misdiagnosis compared with those</cell></row><row><cell>without familial C1-Characteristic</cell><cell>Patients with !1</cell><cell>Patients without a</cell></row><row><cell></cell><cell>misdiagnoses (n ¼ 185)</cell><cell>misdiagnosis (n ¼ 233)</cell></row><row><cell>Age at enrollment, mean (SD)</cell><cell>43.4 (14.2) [1.0e81.6]</cell><cell>38.5 (15.2) [1.0e81.8]</cell></row><row><cell>[range], y</cell><cell></cell><cell></cell></row><row><cell>Female, No. (%)</cell><cell>113 (61.1)</cell><cell>130 (55.8)</cell></row><row><cell>Ethnicity, No. (%) a</cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>174 (95.1)</cell><cell>220 (95.7)</cell></row><row><cell>Asian</cell><cell>5 (2.7)</cell><cell>4 (1.7)</cell></row><row><cell>Other</cell><cell>4 (2.2)</cell><cell>6 (2.6)</cell></row><row><cell>C1-INH-HAE diagnosis, No. (%)</cell><cell></cell><cell></cell></row><row><cell>Type I</cell><cell>169 (91.4)</cell><cell>218 (93.6)</cell></row><row><cell>Type II</cell><cell>16 (8.6)</cell><cell>15 (6.4)</cell></row><row><cell>Age at symptom onset,</cell><cell>14.0 (11.2) [0.1e67.0]</cell><cell>12.9 (11.8) [0.3e77.0]</cell></row><row><cell>mean (SD) [range], y b</cell><cell></cell><cell></cell></row><row><cell>Age at diagnosis, mean (SD)</cell><cell>29.0 (14.7) [3.8e77.3]</cell><cell>20.4 (15.7) [0e77.3]</cell></row><row><cell>[range], y c</cell><cell></cell><cell></cell></row><row><cell>Time from symptom onset to</cell><cell>15.0 (13.4) [13.3]</cell><cell>7.0 (13.2) [1.7]</cell></row><row><cell>C1-INH-HAE diagnosis,</cell><cell></cell><cell></cell></row><row><cell>mean (SD) [median], y d</cell><cell></cell><cell></cell></row><row><cell>No. of attacks per year,</cell><cell>18.9 (21.2) [10.7]</cell><cell>18.9 (27.6) [7.2]</cell></row><row><cell>mean (SD) [median]</cell><cell></cell><cell></cell></row><row><cell>Frequency of attacks per year,</cell><cell></cell><cell></cell></row><row><cell>No. (%) e</cell><cell></cell><cell></cell></row><row><cell>&lt;10 attacks per year</cell><cell>82 (48.8)</cell><cell>123 (56.7)</cell></row><row><cell>!10 attacks per year</cell><cell>86 (51.2)</cell><cell>94 (43.3)</cell></row><row><cell cols="3">Abbreviations: C1-INH-HAE, hereditary angioedema due to C1 inhibitor deficiency;</cell></row><row><cell>HAE, hereditary angioedema.</cell><cell></cell><cell></cell></row></table><note><p><s>a Data reported for 183 patients with 1 or more misdiagnoses and 230 patients without a misdiagnosis.</s><s>b Data reported for 177 patients with 1 or more misdiagnoses and 204 patients without a misdiagnosis.</s><s>c Data reported for 183 patients with 1 or more misdiagnoses and 220 patients without a misdiagnosis.</s><s>d Data reported for 176 patients with 1 or more misdiagnoses and 198 patients without a misdiagnosis.</s><s>e Data reported for 168 patients with 1 or more misdiagnoses and 217 patients without a misdiagnosis.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Allergic Angioedema and Appendicitis MisdiagnosesIn patients who reported 1 or more misdiagnoses (Fig1), the most common diagnoses were allergic angioedema (103 of 185 [55.7%]) and appendicitis (50 of 185 [27.0%]).</s><s>Misdiagnoses were reported by 169 of 387 patients with C1-INH-HAE type I (43.7%) and by 16 of 31 patients with type II (51.6%) (P ¼ .39).</s><s>The percentage of patients reporting each misdiagnosis type was similar between both C1-INH-HAE types (Fig 2).</s><s>The percentages of patients who reported 1 or more misdiagnoses were not statistically different between males (72 of 175 [41.1%]) and females (113 of 243 [46.5%]) (P ¼ .28).</s><s>Similarly, the types of misdiagnosis were not different between males and females (Fig 3).</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p><s>Patient Misdiagnosis by Family History of HAE</s></p></div></figDesc><table><row><cell>Previous misdiagnosis</cell><cell cols="2">No. (%) of patients with family history of HAE</cell></row><row><cell></cell><cell>Yes</cell><cell>No</cell></row><row><cell>Yes</cell><cell>140 (41.7)</cell><cell>38 (65.5)</cell></row><row><cell>No</cell><cell>196 (58.3)</cell><cell>20 (34.5)</cell></row><row><cell>Total a</cell><cell>336</cell><cell>58</cell></row><row><cell cols="2">Abbreviation: HAE, hereditary angioedema.</cell><cell></cell></row><row><cell cols="3">a Data available for both family history and misdiagnosis; missing or unknown data</cell></row><row><cell>were excluded.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc><div><p><s>Country-Specific Rate of C1-INH-HAE Misdiagnosis From IOS Patients a</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No. (%) of</cell><cell>patients</cell><cell>without a</cell><cell>misdiagnosis</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>&gt;1990</cell><cell>No. (%) of</cell><cell>patients</cell><cell>with !1</cell><cell>misdiagnoses</cell><cell>(n ¼ 7)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No. (%) of</cell><cell>patients</cell><cell>without a</cell><cell>misdiagnosis</cell><cell>(n ¼ 54)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1980e1989</cell><cell>No. (%) of</cell><cell>patients</cell><cell>with !1</cell><cell>misdiagnoses</cell><cell>(n ¼ 36)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No. (%) of</cell><cell>patients</cell><cell>without a</cell><cell>misdiagnosis</cell><cell>(n ¼ 57)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1970e1979</cell><cell>No. (%) of</cell><cell>patients</cell><cell>with !1</cell><cell>misdiagnoses</cell><cell>(n ¼ 41)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No. (%) of</cell><cell>patients</cell><cell>without a</cell><cell>misdiagnosis</cell><cell>(n ¼ 42)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1960e1969</cell><cell>No. (%) of</cell><cell>patients</cell><cell>with !1</cell><cell>misdiagnoses</cell><cell>(n ¼ 54)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No. (%) of</cell><cell>patients</cell><cell>without a</cell><cell>misdiagnosis</cell><cell>(n ¼ 28)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1950e1959</cell><cell>No. (%) of</cell><cell>patients</cell><cell>with !1</cell><cell>misdiagnoses</cell><cell>(n ¼ 27)</cell></row><row><cell>IOS country Austria Brazil</cell><cell>No. (%) of patients with !1 misdiagnoses (n ¼ 185) 11 (84.6) 16 (84.2)</cell><cell>No. (%) of patients without a misdiagnosis (n ¼ 233) 2 (15.4) 3 (15.8)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No. (%) of</cell><cell>patients</cell><cell>without a</cell><cell>misdiagnosis</cell><cell>(n ¼ 20)</cell></row><row><cell>Denmark</cell><cell>15 (68.2)</cell><cell>7 (31.8)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Greece Italy United Kingdom Israel Germany France Spain Sweden</cell><cell>12 (63.2) 28 (46.7) 26 (46.4) 22 (41.5) 27 (35.5) 6 (28.6) 22 (28.6) 0 (0.0)</cell><cell>7 (36.8) 32 (53.3) 30 (53.6) 31 (58.5) 49 (64.5) 15 (71.4) 55 (71.4) 2 (100.0)</cell><cell>Table 4</cell><cell>Misdiagnosis by Decade of Birth a</cell><cell>IOS country Year of birth</cell><cell>&lt;1950</cell><cell>No. (%) of</cell><cell>patients</cell><cell>with !1</cell><cell>misdiagnoses</cell><cell>(n ¼ 20)</cell></row></table><note><p><s>Abbreviations: C1-INH-HAE, hereditary angioedema due to C1 inhibitor deficiency; IOS, Icatibant Outcome Survey.aThenumbers of patients by country with missing misdiagnosis data are as follows:France, n ¼ 182; Germany, n ¼ 11; United Kingdom, n ¼ 8; Spain, n ¼ 7; Israel, n ¼ 4; Denmark, n ¼ 2; and Italy, n ¼ 1.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Figure 1.Percentage of patients with hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) by misdiagnosis (n ¼ 185).Patients may have reported more than 1 misdiagnosis.For other misdiagnoses, see Table 5. GERD indicates gastroesophageal reflux disease.GERD indicates gastroesophageal reflux disease.Figure 3. Percentage of patients with hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) by misdiagnosis according to sex.Patients may have reported more than 1 misdiagnosis.For other misdiagnoses, see Table5.</s><s>GERD indicates gastroesophageal reflux disease.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>80</cell><cell>68.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(11)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patients by</cell><cell>Misdiagnosis, % (No.)</cell><cell>20 40 60</cell><cell>54.4 (92)</cell><cell>27.2 (46) 25.0 (4)</cell><cell>24.3 (41)</cell><cell>12.5</cell><cell>20.7 (35)</cell><cell>18.8 (3)</cell><cell cols="2">C1-INH-HAE type I (n = 169) C1-INH-HAE type II (n = 16)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(2)</cell><cell></cell><cell></cell><cell>5.3 (9)</cell><cell>6.3 (1)</cell><cell>4.7 (8)</cell><cell>6.3 (1)</cell><cell>3.6 (6)</cell><cell>6.3 (1)</cell></row><row><cell></cell><cell></cell><cell>0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Allergic</cell><cell cols="3">Appendicitis Other</cell><cell cols="2">Other</cell><cell cols="2">Biliary</cell><cell>GERD</cell><cell>Peptic</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Angioedema</cell><cell></cell><cell></cell><cell cols="2">Nonallergic</cell><cell cols="2">Disorder</cell><cell>Ulcer</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Angioedema</cell></row></table><note><p><s>Figure 2. Percentage of patients with hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) by misdiagnosis according to C1-INH-HAE type I or II.</s><s>Patients may have reported more than 1 misdiagnosis.</s><s>For other misdiagnoses, see</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 5</head><label>5</label><figDesc><div><p><s>Time (in Years) From First Symptoms to C1-INH-HAE Diagnosis by Type of Prior Misdiagnosis in 185 Patients</s></p></div></figDesc><table><row><cell>Prior misdiagnosis</cell><cell cols="2">Time from first symptoms to misdiagnosis, y</cell></row><row><cell></cell><cell>Mean (SD)</cell><cell>Median (range)</cell></row><row><cell>Allergic angioedema (n ¼ 97)</cell><cell>15.5 (13.9)</cell><cell>14.8 (À13.5 to 67.3)</cell></row><row><cell>Appendicitis (n ¼ 47)</cell><cell>13.3 (13.8)</cell><cell>12.0 (À1.2 to 67.3)</cell></row><row><cell>Other a (n ¼ 40)</cell><cell>15.1 (12.0)</cell><cell>13.3 (À0.4 to 46.2)</cell></row><row><cell cols="2">Nonallergic angioedema (n ¼ 38) 18.0 (14.0)</cell><cell>15.7 (À1.2 to 56.6)</cell></row><row><cell>Biliary disorder (n ¼ 10)</cell><cell>16.0 (10.9)</cell><cell>15.8 (0.0 to 34.4)</cell></row><row><cell>GERD (n ¼ 8)</cell><cell>16.1 (11.1)</cell><cell>14.4 (À0.4 to 34.4)</cell></row><row><cell>Peptic ulcer (n ¼ 7)</cell><cell>18.2 (19.7)</cell><cell>13.4 (À0.4 to 54.0)</cell></row><row><cell cols="3">Abbreviations: C1-INH-HAE, hereditary angioedema due to C1 inhibitor deficiency;</cell></row><row><cell cols="2">GERD, gastroesophageal reflux disease.</cell><cell></cell></row></table><note><p><s>a Other diagnoses as reported by patients include colic, colic (gastroenteritis), edema after trauma, endometriosis, familial Mediterranean fever, indigestion, leukemia, rheuma, tonsillitis, urinary tract infection, urticaria, acetonemic vomiting, allergy, bowel obstruction, cardia/neoplasia, colitis, constipation, diverticulitis, dubious fluid in abdomen, gastroenteritis, heartburn, Helicobacter pylori, irritable bowel disease, irritable colon, kidney problem, orchitis (acute gastroenteritis), pancreatitis, psychological overstress syndrome, skin and kidney disorder, stress (acute gastroenteritis), and urticaria (tonsillitis).</s><s>Patients could have reported more than 1 misdiagnosis.</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>and speaker for CSL Behring and Shire, receiving funding to attend conferences or other educational events, donations to his departmental fund, and participating in clinical trials for Shire.</s><s>Dr Fabien reported being a full-time employee of Shire, Zug, Switzerland at the time the analysis was conducted and during the development of the manuscript.</s><s>Dr Andresen reported being a full-time employee of Shire, Zug, Switzerland.</s><s>Dr Caballero reported receiving speaker fees from CSL Behring, Glax-oSmithKline, MSD, Novartis, and Shire; consultancy fees from CSL Behring, Novartis, Shire, and Sobi; funding for travel and meeting attendance from CSL Behring, Novartis, and Shire; and participating in clinical trials or registries for CSL Behring, Dyax, Novartis, Pharming, and Shire.</s><s>Funding Sources: The Icatibant Outcome Survey is funded by Shire, Zug, Switzerland.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond</title>
		<author>
			<persName><forename type="first">A</forename><surname>Agostoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Aygören-Pürsün</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Binkley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S51" to="S131" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Hereditary angioedema: new findings concerning symptoms, affected organs, and course</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="267" to="e274" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">WAO guideline for the management of hereditary angioedema</title>
		<author>
			<persName><forename type="first">T</forename><surname>Craig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Aygören-Pürsün</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bork</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Allergy Organ J</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="182" to="e199" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cicardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Banerji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="602" to="e616" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Lumry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="S103" to="S110" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Witzke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="692" to="e697" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain</title>
		<author>
			<persName><forename type="first">O</forename><surname>Roche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Blanch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Caballero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sastre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Callejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>López-Trascasa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="498" to="e503" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zanichelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Longhurst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Fabien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">29</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Lunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Craig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="211" to="e214" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zanichelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Arcoleo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Barca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Orphanet J Rare Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">11</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Hereditary angio-oedema in Denmark: a nationwide survey</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bygum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="1153" to="e1158" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Hereditary angioedema. Diagnostic and treatment errors as systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">P</forename><surname>Harten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Korbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Renk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Euler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Loffler</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>in German</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Med Klin (Munich)</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="339" to="e344" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Recurrent attacks of hereditary angioedema: a case of delayed diagnosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Jacobs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S23" to="S26" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Misdiagnosis of hereditary angio-oedema type 1 and type 2</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gompels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Unsworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Archer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Davies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="719" to="e723" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Gastrointestinal manifestations, diagnosis, and management of hereditary angioedema</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jalaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Scolapio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="817" to="e823" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Diagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">C</forename><surname>Nzeako</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="4913" to="e4921" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Asphyxiation by laryngeal edema in patients with hereditary angioedema</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Siedlecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Schopf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kreuz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mayo Clin Proc</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="349" to="e354" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cicardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Banerji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bracho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="532" to="e541" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Longhurst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Fabien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Lumry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="377" to="e381" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bouillet</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">O S</forename><surname>Investigators</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e53773</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema</title>
		<author>
			<persName><forename type="first">E</forename><surname>Pappalardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cicardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Duponchel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1147" to="e1154" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">C</forename><surname>Nzeako</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Longhurst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="353" to="e361" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe</title>
		<author>
			<persName><forename type="first">E</forename><surname>Aygören-Pürsün</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bygum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beusterien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Orphanet J Rare Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">99</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Burden of illness in hereditary angioedema: a conceptual model</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bygum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Aygören-Pürsün</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beusterien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="706" to="e710" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Lumry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Castaldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Vernon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Blaustein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Horn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="407" to="e414" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Economic costs associated with acute attacks and long-term management of hereditary angioedema</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Shea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Rentz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Blaustein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Pullman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="314" to="e320" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The humanistic, societal, and pharmaco-economic burden of angioedema</title>
		<author>
			<persName><forename type="first">H</forename><surname>Longhurst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bygum</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12016-016-8575-2</idno>
		<ptr target="http://dx.doi.org/10.1007/s12016-016-8575-2" />
	</analytic>
	<monogr>
		<title level="j">Clin Rev Allergy Immunol</title>
		<imprint/>
	</monogr>
	<note>published online July 7, 2016</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan</title>
		<author>
			<persName><forename type="first">I</forename><surname>Ohsawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Honda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nagamachi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="492" to="e498" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema</title>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Doumoulakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kalkounou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="298" to="e303" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
